2022/09/26 News Release Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
2022/07/06 News Release UBE Corporation to Begin Basic Design for DMC and EMC Plant Construction in the U.S.
2022/06/10 News Release Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension
2022/04/28 News Release UBE Corporation Announces Change of Representative Director and Personnel Change
2022/04/12 News Release UBE Group Announces New Medium-Term Targets by 2030 for Achieving Carbon Neutrality by 2050
2022/04/07 News Release UBE Corporation Selected as a Constituent of FTSE Blossom Japan Sector Relative Index
2022/03/28 News Release Ube Industries and HiLung Sign Joint Development Agreement for Co-Development of Novel Selective LPA1 Antagonist HL001 for Pulmonary Fibrosis
2022/03/23 News Release Ube Industries and Kirilys Therapeutics, Inc. Sign License Agreement for CDK7 inhibitors
2022/02/28 News Release Shionogi and Ube Industries Enter into a Strategic Development Collaboration for the Novel Anti-RS Virus Drug Candidate S-337395
2021/12/24 News Release In antiplatelet agents Efient® Tablets 3.75 mg and Efient® Tablets 2.5 mg Supplemental New Drug Application Approval for Additional Indication, Dosage and Administration in Japan
